AIM: To evaluate the efficacy and safety of intravitreal bevacizumab(Avastin)for choroidal neovascularization(CNV)in pathologic myopia(PM)by including optical coherence tomography(OCT), fluorescein angiography(FFA)and best-corrected visual acuity(BCVA).

METHODS: Totally 42 eyes in 41 patients with PM CNV were divided into 2 groups randomly, experimental group(n=22)were assigned to receive intravitreal bevacizumab injections and take fufangxueshuantong capsule; control group(n=20)just took fufangxueshuantong capsule. Subjects were followed up every month after treatment. The efficacy and safety of two group were compared by ophthalmic evaluations including OCT, FFA, and BCVA.

RESULTS: BCVA: BCVA in two groups was improved after 12 months. The mean number of treatments per eye, experimental group was 4.23±2.02 and control group was 1.95±1.90. There was significant difference(P<0.005). OCT: Before and after 12 months central foveal thickness(CFD)for two groups were thin,and the mean value in experimental group was 43.41±40.39μm and in control group was 22.65±20.79μm, there was significant difference(P<0.05); FFA: In experimental group CNV was completely disappeared in 20 eyes(91%), persistent in 2 eyes(9%); the control group CNV was completely disappeared in 12 eyes(60%), persistent in 8 eyes(40%). There was significant difference(P<0.05).

CONCLUSION: Intravitreal bevacizumab are safe and effective treatment for most patients of CNV in PM.